Search information pages
About Molecular Neurodegeneration
This page includes information about the aims and scope of Molecular Neurodegeneration, editorial policies, open access and article-processing charges, the peer review process and other information. For details of how to prepare and submit a manuscript through the online submission system, please see the instructions for authors.
Aims & scope
Molecular Neurodegeneration is an open access, peer-reviewed online journal that encompasses all aspects of neurodegeneration research at the molecular and cellular levels.
Neurodegenerative diseases collectively refer to neurological disorders that result from neurodegeneration and include, but are not limited to, Alzheimer's disease, Parkinson's disease, Huntington's disease, and prion diseases. These diseases, which are often associated with advanced aging and display varying degrees of dementia, have become a significant public health issue as humans live longer and the aging population grows larger. Recent advances in the molecular and cellular mechanisms underlying the pathogenesis of these neurodegenerative disorders have allowed for a better understanding of the disease mechanisms.
All articles published by Molecular Neurodegeneration are made freely and permanently accessible online immediately upon publication, without subscription charges or registration barriers. Further information about open access can be found here.
Authors of articles published in Molecular Neurodegeneration are the copyright holders of their articles and have granted to any third party, in advance and in perpetuity, the right to use, reproduce or disseminate the article, according to the BioMed Central copyright and license agreement.
For authors who are US government employees or are prevented from being copyright holders for similar reasons, BioMed Central can accommodate non-standard copyright lines. Please contact us if further information is needed.
Open access publishing is not without costs. Molecular Neurodegeneration therefore levies an article-processing charge of £1515/$2370/€1930 for each article accepted for publication. If the submitting author's institution is a Member, the cost of the article-processing charge is covered by the membership, and no further charge is payable. In the case of authors whose institutions are Supporter Members, however, a discounted article-processing charge is payable by the author. We routinely waive charges for authors from low-income countries. For other countries, article-processing charge waivers or discounts are granted on a case-by-case basis to authors with insufficient funds. Authors can request a waiver or discount during the submission process. For further details, see our article-processing charge page.
All articles published in Molecular Neurodegeneration are included in PubMed, the most widely used biomedical bibliographic database service, which is run by the US National Library of Medicine. Other bibliographic databases that index articles published in Molecular Neurodegeneration include:
- Biological Abstracts
- Google Scholar
- PubMed Central
- Science Citation Index Expanded
The full text of all research articles is deposited in PubMed Central, the US National Library of Medicine's full-text repository of life science literature, and other digital archives including e-Depot (The Netherlands).
The full text of all research articles published by BioMed Central is also available on SpringerLink.
Molecular Neurodegeneration is tracked by Thomson Reuters (ISI) and has an Impact Factor of 6.56.
Publication and peer review process
Criteria for publication
Molecular Neurodegeneration considers the following types of articles:
- Commentary: short, focused and opinionated articles on any subject within the journal's scope. These articles are usually related to a contemporary issue, such as recent research findings, and are often written by opinion leaders invited by the Editorial Board. They focus on specific issues and are about 800 words in length. Commentaries can be broken down into several types including ethics, technology, research-related, review-related, general interest, debates and reviews of recently published articles from other journals in the field.
- Meeting report: a short description of a conference that the author has attended. It is usually best for the article to be published as soon after the meeting as possible, and should focus on the key developments presented and discussed at the meeting. These articles are usually commissioned but reports and suggestions may also be submitted for the Editors' consideration.
- Methodology: presentations of a new experimental method, test or procedure. The method described may either be completely new, or may offer a better version of an existing method. The article must describe a demonstrable advance on what is currently available. The method needs to have been well tested and ideally, but not necessarily, used in a way that proves its value.
- Research: reports of data from original research.
- Review: comprehensive, authoritative, descriptions of any subject within the journal's scope. Opinion leaders that have been invited by the Editorial Board usually write these articles. They have an educational aim and are 2000-3000 words. Long reviews and short reviews have different readerships and characteristics - a mixture of both is ideal. Reviews can cover any topical themes such as basic science and clinical reviews, ethics, pro/con debates, equipment reviews and thematic series to highlight specific topics in your field.
- Short report: brief reports of data from original research, usually about 1500 words.
Manuscripts that are deemed suitable for peer review will be assigned to two expert reviewers. Reviewers may either be Editorial Board members or external experts selected by the Editors. The reviewers will have up to three weeks to review the submitted article. The final decision to accept or reject a manuscript will be made by one of the Editors-in-Chief.
Authors will be able to check the progress of their manuscript through the submission system at any time by logging into My Molecular Neurodegeneration, a personalized section of the site.
High-quality, bound reprints can be purchased for all articles published. Please see our reprints website for further information about ordering reprints.
Molecular Neurodegeneration will consider supplements based on proceedings (full articles or meeting abstracts), reviews or research. All articles submitted for publication in supplements are subject to peer review. Published supplements are fully searchable and freely accessible online and can also be produced in print. All full length articles (proceedings, reviews or research articles) are indexed by PubMed. PubMed displays the title of the supplement only in the case of meeting abstract collections. For further information, please contact us.
All manuscripts submitted to Molecular Neurodegeneration should adhere to BioMed Central's editorial policies.
Citing articles in Molecular Neurodegeneration
Articles in Molecular Neurodegeneration should be cited in the same way as articles in a traditional journal. Because articles are not printed, they do not have page numbers; instead, they are given a unique article number.
Article citations follow this format:
Authors: Title. Mol Neurodegeneration [year], [volume number]:[article number].
e.g. Roberts LD, Hassall DG, Winegar DA, Haselden JN, Nicholls AW, Griffin JL: Increased hepatic oxidative metabolism distinguishes the action of Peroxisome Proliferator-Activated Receptor delta from Peroxisome Proliferator-Activated Receptor gamma in the Ob/Ob mouse. Mol Neurodegeneration 2009, 1:115.
refers to article 115 from Volume 1 of the journal.
Why publish your article in Molecular Neurodegeneration?
Molecular Neurodegeneration's open access policy allows maximum visibility of articles published in the journal as they are available to a wide, global audience. Articles that have been especially highly accessed are highlighted with a 'Highly accessed' graphic, which appears on the journal's contents pages and search results.
Speed of publication
Molecular Neurodegeneration offers a fast publication schedule whilst maintaining rigorous peer review; all articles must be submitted online, and peer review is managed fully electronically (articles are distributed in PDF form, which is automatically generated from the submitted files). Articles will be published with their final citation after acceptance, in both fully browsable web form, and as a formatted PDF; the article will then be available through Molecular Neurodegeneration, BioMed Central and PubMed Central and will also be included in PubMed.
Online publication in Molecular Neurodegeneration gives authors the opportunity to publish large datasets, large numbers of color illustrations and moving pictures, to display data in a form that can be read directly by other software packages so as to allow readers to manipulate the data for themselves, and to create all relevant links (for example, to PubMed, to sequence and other databases, and to other articles).
Promotion and press coverage
Articles published in Molecular Neurodegeneration are included in article alerts and regular email updates. Some may be included in abstract books mailed to academics and are highlighted on Molecular Neurodegeneration's pages and on the BioMed Central homepage.
In addition, articles published in Molecular Neurodegeneration may be promoted by press releases to the general or scientific press. These activities increase the exposure and number of accesses for articles published in Molecular Neurodegeneration. A list of articles recently press-released by journals published by BioMed Central is available here.
Authors of articles published in Molecular Neurodegeneration retain the copyright of their articles and are free to reproduce and disseminate their work (for further details, see the BioMed Central copyright policy and license agreement).
For further information about the advantages of publishing in a journal from BioMed Central, please click here.